This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baker, S. G Articles by Skates, S. Search for Related Content PubMed PubMed Citation Articles by Baker, S. G Articles by Skates, S. Social Bookmarking                         What's this?

Evaluating markers for the early detection of cancer: overview of study designs and methods

National Institutes of Health, Bethesda; National Cancer Institute, EPN 3131,6130 Executive Blvd MSC 7354, Bethesda, MD 20892-7354, USA sb16i{at}nih.gov

Barnett S Kramer

National Institutes of Health, Bethesda, MD, USA

Martin McIntosh

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Blossom H Patterson

National Institutes of Health, Bethesda, MD, USA

Yu Shyr

Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Steven Skates

Massachusetts General Hospital, Boston, MA, USA

Background The field of cancer biomarker development has been evolving rapidly. New developments both in the biologic and statistical realms are providing increasing opportunities for evaluation of markers for both early detection and diagnosis of cancer.

Purpose To review the major conceptual and methodological issues in cancer biomarker evaluation, with an emphasis on recent developments in statistical methods together with practical recommendations.

Methods We organized this review by type of study: preliminary performance, retrospective performance, prospective performance and cancer screening evaluation.

Results For each type of study, we discuss methodologic issues, provide examples and discuss strengths and limitations.

Conclusion Preliminary performance studies are useful for quickly winnowing down the number of candidate markers; however their results may not apply to the ultimate target population, asymptomatic subjects. If stored specimens from cohort studies with clinical cancer endpoints are available, retrospective studies provide a quick and valid way to evaluate performance of the markers or changes in the markers prior to the onset of clinical symptoms. Prospective studies have a restricted role because they require large sample sizes, and, if the endpoint is cancer on biopsy, there may be bias due to overdiagnosis. Cancer screening studies require very large sample sizes and long follow-up, but are necessary for evaluating the marker as a trigger of early intervention.

Clinical Trials, Vol. 3, No. 1, 43-56 (2006)
DOI: 10.1191/1740774506cn130oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. G. Baker Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests J Natl Cancer Inst, August 19, 2009; 101(16): 1116 - 1119. [Abstract] [Full Text] [PDF]

				I. Horvath, Z. Lazar, N. Gyulai, M. Kollai, and G. Losonczy Exhaled biomarkers in lung cancer Eur. Respir. J., July 1, 2009; 34(1): 261 - 275. [Abstract] [Full Text] [PDF]

				M. S. Pepe, Z. Feng, H. Janes, P. M. Bossuyt, and J. D. Potter Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design J Natl Cancer Inst, October 15, 2008; 100(20): 1432 - 1438. [Abstract] [Full Text] [PDF]

				W. S. Dalton and S. H. Friend Cancer biomarkers--an invitation to the table. Science, May 26, 2006; 312(5777): 1165 - 1168. [Abstract] [Full Text] [PDF]